DSY Dassault Systemes SA

Dassault Systèmes: Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey

Dassault Systèmes: Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey

Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey 

Expanded 10-plus-year collaboration will leverage Medidata Experiences, enabling Sanofi to streamline operations, refine data quality, and enhance patient care

New York – Oct. 23, 2025 –, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, and today announced an expansion of their partnership to bolster clinical research. This new agreement will take advantage of the , building on both organizations’ shared vision to boost innovation in studies, speed new therapies to market, and promote health outcomes for people globally.

The Medidata Experiences address the fragmented, standalone tools of the life sciences industry by offering AI-embedded, platform-based solutions across clinical workflows, unifying trial processes, diminishing silos, and reducing costs and delays. Combining these Experiences with Sanofi’s pharmaceutical knowledge will advance studies, amplifying the development of therapies with greater precision and impact.

“Sanofi and Medidata have worked together for a decade within clinical research, including a in 2024,” said Gaelan Ritter, global head of digital clinical development, Sanofi. “With this broadened relationship, we will continue harnessing the power of AI, optimizing our clinical trials, and ultimately expediting the delivery of groundbreaking medicines.”

Sanofi will employ Medidata’s expertise and capabilities in as part of this new enterprise agreement. Medidata will also provide strategic consulting and end-to-end operational support, empowering Sanofi to further streamline research processes.

“Clinical development is complex, and biopharma companies demand a strategic partner who can help them enhance data quality, improve study design, and elevate patient care," said Lisa Moneymaker, chief strategy officer, Medidata. "Through our alliance, Sanofi can leverage our unified solutions, specifically mapped out to meet their core needs, to simplify execution and accelerate the entire clinical development process.”

To learn more about the Medidata Experiences, please visit .

About Medidata

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 36,000 trials and 11 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and one of the largest clinical trial data sets in the industry. More than 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at . Listen to our latest podcast, , and follow us at @Medidata.

About Dassault Systèmes

Dassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. With Dassault Systèmes’ 3DEXPERIENCE platform, 370,000 customers of all sizes, in all industries, can collaborate, imagine and create sustainable innovations that drive meaningful impact. For more information, visit: .

About Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Contact:

Medidata PR

Analyst Relations

Sanofi PR

Sandrine Guendoul |

Evan Berland |

Léo Le Bourhis |

Victor Rouault |

Timothy Gilbert |

Léa Ubaldi |

Attachment



EN
23/10/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Dassault Systemes SA

 PRESS RELEASE

Dassault Systèmes’ CEO Pascal Daloz becomes also Chairman of the Board...

Dassault Systèmes’ CEO Pascal Daloz becomes also Chairman of the Board of Directors of Dassault Systèmes Press ReleaseVELIZY-VILLACOUBLAY, France — February 21, 2026 Dassault Systèmes’ CEO Pascal Daloz becomes also Chairman of the Board of Directors of Dassault Systèmes Bernard Charlès announces stepping down from his Executive Chairman and Member of the Board positions, for personal reasonsBernard Charlès intends to put his 43 years of industry experience, and his vision to transform, with AI, industrial creation and production processes, at the service of the Generative Economy Pascal D...

 PRESS RELEASE

Dassault Systèmes annonce la nomination de Pascal Daloz comme Préside...

Dassault Systèmes annonce la nomination de Pascal Daloz comme Président-Directeur Général de Dassault Systèmes Communiqué de PresseVELIZY-VILLACOUBLAY – 21 Février 2026 Dassault Systèmes annonce la nomination de Pascal Daloz comme Président-Directeur Général de Dassault Systèmes Bernard Charlès annonce se retirer de ses fonctions de Président du Conseil et d’administrateur, pour raisons personnelles Bernard Charlès entend mettre ses 43 années d’expérience dans l’industrie, ainsi que sa vision de la transformation par l’IA des processus industriels de création et de production, au servic...

 PRESS RELEASE

Dassault Systèmes: disclosure of trading in own shares

Dassault Systèmes: disclosure of trading in own shares Press ReleaseVELIZY-VILLACOUBLAY, France — February 18, 2026                  DISCLOSURE OF TRADING IN OWN SHARES(Repurchase program decided by the General Meeting of Shareholders of May 22, 2025) Issuer: (Euronext Paris: FR0014003TT8, DSY.PA)Type of securities: Ordinary sharesPeriod: February 12 and February 13, 2026 Presentation of the trading in own shares by day and by market Name of issuerIdentification code of the issuerDate of tradingIdentification code of the financial instrumentDaily total volume (in number of shares)Daily...

 PRESS RELEASE

Dassault Systèmes : opérations sur actions propres

Dassault Systèmes : opérations sur actions propres Communiqué de PresseVELIZY-VILLACOUBLAY, France — le 18 février 2026 DECLARATION DES OPERATIONS SUR ACTIONS PROPRES (Programme de rachat adopté par l’Assemblée Générale du 22 mai 2025)         Emetteur : (Euronext Paris: FR0014003TT8, DSY.PA)Catégorie de titres : Actions ordinairesPériode : du 12 au 13 février 2026 Présentation agrégée par jour et par marché Nom de l'émetteurCode Identifiant de l'émetteurJour de la transactionCode identifiant de l'instrument financierVolume total journalier (en nombre d'actions)Prix pondéré moyen journa...

 PRESS RELEASE

Dassault Systèmes: Q4 revenue growth of 1% with solid operating margin...

Dassault Systèmes: Q4 revenue growth of 1% with solid operating margin and EPS expansion Initiating 2026 revenue guidance of 3-5% growth Press Release VELIZY-VILLACOUBLAY, France — February 11, 2026 Dassault Systèmes: Q4 revenue growth of 1% with solid operating margin and EPS expansion Initiating 2026 revenue guidance of 3-5% growth            (Euronext Paris: FR0014003TT8, DSY.PA) today reports its IFRS unaudited estimated financial results for the fourth quarter 2025 and full-year ended December 31, 2025. The Group’s Board of Directors approved these estimated results on February...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch